Schwab I - Search Results

1

Pathways Responsible for Human Autoantibody and Therapeutic Intravenous IgG Activity in Humanized Mice.

Schwab I, Lux A, Nimmerjahn F. Schwab I, et al. Cell Rep. 2015 Oct 20;13(3):610-620. doi: 10.1016/j.celrep.2015.09.013. Epub 2015 Oct 8. Cell Rep. 2015. PMID: 26456831 Free article.

2

Controlled tetra-Fc sialylation of IVIg results in a drug candidate with consistent enhanced anti-inflammatory activity.

Washburn N, Schwab I, Ortiz D, Bhatnagar N, Lansing JC, Medeiros A, Tyler S, Mekala D, Cochran E, Sarvaiya H, Garofalo K, Meccariello R, Meador JW 3rd, Rutitzky L, Schultes BC, Ling L, Avery W, Nimmerjahn F, Manning AM, Kaundinya GV, Bosques CJ. Washburn N, et al. Among authors: schwab i. Proc Natl Acad Sci U S A. 2015 Mar 17;112(11):E1297-306. doi: 10.1073/pnas.1422481112. Epub 2015 Mar 2. Proc Natl Acad Sci U S A. 2015. PMID: 25733881 Free PMC article.

3

Reply to - IVIG pluripotency and the concept of Fc-sialylation: challenges to the scientist.

Schwab I, Lux A, Nimmerjahn F. Schwab I, et al. Nat Rev Immunol. 2014 May;14(5):349. doi: 10.1038/nri3401-c2. Nat Rev Immunol. 2014. PMID: 24762828 No abstract available.

4

Targeting B cells and autoantibodies in the therapy of autoimmune diseases.

Kao D, Lux A, Schwab I, Nimmerjahn F. Kao D, et al. Among authors: schwab i. Semin Immunopathol. 2014 May;36(3):289-99. doi: 10.1007/s00281-014-0427-7. Epub 2014 Apr 29. Semin Immunopathol. 2014. PMID: 24777745 Review.

5

Elucidating the interplay between IgG-Fc valency and FcγR activation for the design of immune complex inhibitors.

Ortiz DF, Lansing JC, Rutitzky L, Kurtagic E, Prod'homme T, Choudhury A, Washburn N, Bhatnagar N, Beneduce C, Holte K, Prenovitz R, Child M, Killough J, Tyler S, Brown J, Nguyen S, Schwab I, Hains M, Meccariello R, Markowitz L, Wang J, Zouaoui R, Simpson A, Schultes B, Capila I, Ling L, Nimmerjahn F, Manning AM, Bosques CJ. Ortiz DF, et al. Among authors: schwab i. Sci Transl Med. 2016 Nov 16;8(365):365ra158. doi: 10.1126/scitranslmed.aaf9418. Sci Transl Med. 2016. PMID: 27856797

6

Siglec-G Deficiency Leads to Autoimmunity in Aging C57BL/6 Mice.

Müller J, Lunz B, Schwab I, Acs A, Nimmerjahn F, Daniel C, Nitschke L. Müller J, et al. Among authors: schwab i. J Immunol. 2015 Jul 1;195(1):51-60. doi: 10.4049/jimmunol.1403139. Epub 2015 May 18. J Immunol. 2015. PMID: 25987743 Free article.

7

A humanized mouse identifies the bone marrow as a niche with low therapeutic IgG activity.

Lux A, Seeling M, Baerenwaldt A, Lehmann B, Schwab I, Repp R, Meidenbauer N, Mackensen A, Hartmann A, Heidkamp G, Dudziak D, Nimmerjahn F. Lux A, et al. Among authors: schwab i. Cell Rep. 2014 Apr 10;7(1):236-48. doi: 10.1016/j.celrep.2014.02.041. Epub 2014 Mar 27. Cell Rep. 2014. PMID: 24685130 Free article.

8

Broad requirement for terminal sialic acid residues and FcγRIIB for the preventive and therapeutic activity of intravenous immunoglobulins in vivo.

Schwab I, Mihai S, Seeling M, Kasperkiewicz M, Ludwig RJ, Nimmerjahn F. Schwab I, et al. Eur J Immunol. 2014 May;44(5):1444-53. doi: 10.1002/eji.201344230. Epub 2014 Mar 7. Eur J Immunol. 2014. PMID: 24505033 Free article.

9

Intravenous immunoglobulin therapy: how does IgG modulate the immune system?

Schwab I, Nimmerjahn F. Schwab I, et al. Nat Rev Immunol. 2013 Mar;13(3):176-89. doi: 10.1038/nri3401. Epub 2013 Feb 15. Nat Rev Immunol. 2013. PMID: 23411799 Review.

10

B cells and CD22 are dispensable for the immediate antiinflammatory activity of intravenous immunoglobulins in vivo.

Schwab I, Seeling M, Biburger M, Aschermann S, Nitschke L, Nimmerjahn F. Schwab I, et al. Eur J Immunol. 2012 Dec;42(12):3302-9. doi: 10.1002/eji.201242710. Epub 2012 Oct 16. Eur J Immunol. 2012. PMID: 22945870 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results